Extending the reach of BRAF-targeted cancer therapy
Mené sur 184 patients atteints de diverses tumeurs solides, dont 156 atteints d'un mélanome métastatique, cet essai de phase I évalue le dabrafenib, un inhibiteur de l'activité kinase d'une version mutée du gène BRAF
The Lancet, Volume 379, Numéro 9829, Page 1858-1859, 2012, commentaire
Résumé en anglais
In The Lancet , Gerald Falchook and colleagues present results from a phase 1 trial of dabrafenib in patients with incurable solid tumours. In an expansion cohort, patients with BRAF-mutant tumours (including those with non-Val600Glu mutations) from three populations were treated at the recommended phase 2 dose: those with metastatic melanoma, those with non-melanoma solid tumours, and those with active melanoma brain metastases.
